Cisplatinum-induced renal salt wasting

Area of Science:

• Nephrology
• Oncology
• Pharmacology

Background:

• Cisplatinum is a widely used platinum-based chemotherapy agent for various cancers.
• Potential renal toxicities of cisplatinum are recognized, but specific electrolyte disturbances are less understood.

Observation:

• Two patients receiving cisplatinum developed significant salt wasting, evidenced by high urinary sodium and chloride excretion (>130 mmol/L).
• One patient experienced symptomatic hyponatremia during hypotonic fluid administration, while the other developed orthostatic hypotension.
• These electrolyte abnormalities persisted despite no evidence of adrenal insufficiency and lack of response to fludrocortisone.

Findings:

• Cisplatinum administration was associated with marked natriuresis and chloruresis.
• The observed salt wasting was independent of adrenal function and did not respond to mineralocorticoid therapy.

Implications:

• Cisplatinum may induce nephrotoxicity by impairing solute transport in the thick ascending limb of the Loop of Henle.
• This finding highlights a previously unrecognized mechanism of cisplatinum-induced renal toxicity.
• Clinical monitoring for electrolyte imbalances is crucial in patients undergoing chronic cisplatinum therapy.